Our previous study confirmed the ability of Lactobacillus plantarum CCFM8610 to protect against acute cadmium (Cd) toxicity in mice. This study was designed to evaluate the protective effects of CCFM8610 against chronic Cd toxicity in mice and to gain insights into the protection mode of this strain. Experimental mice were divided into two groups and exposed to Cd for 8 weeks via drinking water or intraperitoneal injection. Both groups were further divided into four subgroups, control, Cd only, CCFM8610 only, and Cd plus CCFM8610. Levels of Cd were measured in the feces, liver, and kidneys, and alterations of several biomarkers of Cd toxicity were noted. The results showed that when Cd was introduced orally, cotreatment with Cd and CCFM8610 effectively decreased intestinal Cd absorption, reduced Cd accumulation in tissue, alleviated tissue oxidative stress, reversed hepatic and renal damage, and ameliorated the corresponding histopathological changes. When Cd was introduced intraperitoneally, administration of CCFM8610 did not have an impact on tissue Cd accumulation or reverse the activities of antioxidant enzymes. However, CCFM8610 still offered protection against oxidative stress and reversed the alterations of Cd toxicity biomarkers and tissue histopathology. These results suggest that CCFM8610 is effective against chronic cadmium toxicity in mice. Besides intestinal Cd sequestration, CCFM8610 treatment offers direct protection against Cd-induced oxidative stress. We also provide evidence that the latter is unlikely to be mediated via protection against Cd-induced alteration of antioxidant enzyme activities.
C admium (Cd) is a toxic heavy metal that has a variety of adverse effects on the health of humans and animals. The risk of human exposure to this nonessential metal is increasing because of increasing Cd contamination of the food chain (1). In recent years, there have been many chronic Cd poisoning incidents due to inadequate protection from Cd-contaminated food and industrial material (2) . Therefore, chronic exposure to an environmentally relevant Cd concentration is a greater threat to human health than accidental high-dose exposure (3, 4) . On the basis of epidemiological studies in China, Japan, the United States, and several European countries, populations exposed to environmental Cd over a long period are likely to suffer from toxic effects including renal damage, bone disease, pulmonary disease, hepatic dysfunction, cardiovascular impairment, and cancer (5) (6) (7) (8) (9) .
Many studies have shown that the kidney is a key organ in the progression of chronic Cd toxicity. The mechanism of this nephrotoxicity is believed to be renal proximal tubular cell injury (10, 11) . However, as most of the Cd absorbed during chronic exposure is initially stored in the liver before being transported to the kidney via the bloodstream (12) , the hepatotoxicity of chronic Cd exposure is attracting increasing attention. Available data suggested that chronic Cd exposure can cause significant pathological and functional changes in the liver (13, 14) , indicating that the hepatic damage caused by chronic Cd toxicity should be investigated further.
To date, no specific treatment for chronic Cd poisoning has been developed (2) , and chelation therapies, the most direct treatments to alleviate Cd toxicity by promoting Cd excretion, are deficient in safety and efficacy (15, 16) . Therefore, development of new strategies against Cd toxicity is still required. Recently, we have demonstrated that Lactobacillus plantarum CCFM8610, a selected probiotic with good Cd-binding capability, can significantly protect against acute Cd toxicity in both the livers and kidneys of mice (17) . CCFM8610 can decrease intestinal Cd absorption, reduce Cd accumulation in tissues, and alleviate renal and hepatic oxidative stress. However, it is unclear whether the alleviation of oxidative stress was simply an indirect effect due to the initial intestinal Cd sequestration by CCFM8610, a direct effect related to other biological properties of CCFM8610, or both. Further evidence is needed to establish if CCFM8610 has additional protective properties against Cd beyond the intestinal Cd sequestration capacity. Moreover, it is important to investigate the protective effects of L. plantarum CCFM8610 against the toxic effects of chronic Cd exposure, since the acute Cd exposure model is not suitable for assessing the status of long-term and low-level Cd exposure to environmentally relevant Cd concentrations.
The aims of this study were to evaluate the protective effects of L. plantarum CCFM8610 against chronic Cd toxicity in the livers and kidneys of mice and to gain insight into the protection mode of CCFM8610 by separating its intestinal Cd sequestration activity and identifying its other potential protective functions.
MATERIALS AND METHODS
Chemicals and reagents. Kits used to measure the levels of malondialdehyde (MDA; Njjcbio A003 MDA kit), glutathione (GSH; Njjcbio A006 GSH kit), GSH peroxidase (GPx; Njjcbio A005 GPx kit), superoxide dismutase (SOD; Njjcbio A001 SOD kit), catalase (CAT; Njjcbio A007 CAT kit), aspartate transaminase (AST; Njjcbio C010 AST kit), and alanine transaminase (ALT; Njjcbio C009 ALT kit) were purchased from the Jiancheng Bioengineering Institute (Nanjing, China). Cd chloride and other analytical laboratory chemicals and reagents were purchased from the Sinopharm Chemical Reagent Company (Shanghai, China).
Bacterial strain and culture. L. plantarum CCFM8610 and L. bulgaricus CCFM8004 were obtained from the in-house Culture Collections of Food Microbiology, Jiangnan University (Wuxi, China). The strains were cultured in de Man, Rogosa, and Sharpe broth (Hopebio Company, Qingdao, China) at 37°C for 18 h.
For application of strains in the animal experiments, the cultured cells were washed twice with ultrapure water and centrifuged at 8,000 ϫ g for 20 min to obtain cell pellets. The cell pellets were then lyophilized with skim milk as a protectant and stored at Ϫ20°C. The viability of the freezedried cells was measured by colony counting before the animal experiments. Briefly, freeze-dried cells with skim milk as a protectant were resuspended with ultrapure water. The viability of the cells was recorded as approximately 2 ϫ 10 9 CFU/ml after colony counting. Therefore, in the animal experiments, mice were orally given 0.5 ml of resuspended freezedried cells in skim milk, which corresponded to 1 ϫ 10 9 CFU of bacterial cells.
Animals and experimental design. Adult male C57black/6 mice obtained from the Shanghai Laboratory Animal Center (Shanghai, China) were used in all of the experiments. The mice were kept in stainless steel cages in a temperature-and humidity-controlled room that was equipped to maintain a 12-h light-dark cycle. The mice were fed with standard commercial mouse food, and water was given ad libitum. All of the protocols for this study were approved by the Ethics Committee of Jiangnan University, China (JN no. 20121026-0120-24). The procedures of this study were carried out in accordance with the European Community guidelines (directive 2010/63/EU) for the care and use of experimental animals.
As shown in Table 1 , the mice were divided randomly into two groups. L. plantarum CCFM8610 was provided as a dose of 1 ϫ 10 9 CFU in 0.5 ml of skim milk once daily via gavage. In oral groups, mice were exposed to Cd via Cd-containing drinking water. In the intraperitoneal injection (IP) groups, mice were exposed to Cd via intraperitoneal injection. The mice in both the oral and IP groups were divided into four subgroups, control (no Cd or CCFM8610), Cd only, CCFM8610 only, and Cd plus CCFM8610, with 10 mice in each group. An oral dose of CdCl 2 at 100 mg/liter of drinking water was used for modeling of environmentally relevant, low-concentration Cd exposure (18) (19) (20) (21) . The intraperitoneal injection dose of CdCl 2 was calculated on the basis of data from our preliminary experiment and from the literature to correspond to a daily Cd intake equal to that of the oral exposure group. Briefly, the average daily CdCl 2 intake of each mouse in the oral groups was calculated to be approximately 450 g on the basis of the water consumption of Cd-exposed mice in our preliminary experiment. The intestinal Cd absorption rate of rodents was concluded to be approximately 2% according to previous reports (1, 2). The daily intraperitoneal injection dose of CdCl 2 for each Cd-exposed mouse in the IP groups was thus 9 g to ensure the same level of CdCl 2 absorption in the oral and IP groups. As a comparative control, L. bulgaricus CCFM8004 was used in animal experiments with methods identical to those used for CCFM8610 treatment.
During the 8-week treatment period, weekly measurement of body weight was performed. Each mouse was moved into a clean and empty cage every week for 1 h, and fecal samples were collected. At the end of the 8th week, mice were placed in metabolic cages individually for 24 h and urine was collected. All of the mice were then sacrificed under light ether anesthesia, and blood was collected in heparinized tubes to obtain plasma. The liver and kidneys were excised and washed with saline solution prepared with deionized water and sodium chloride, and samples were removed and fixed in 10% formalin saline for 48 h for histopathological studies. The remaining liver and kidney tissues were collected in metalfree Eppendorf tubes and stored at Ϫ80°C for the biochemical assays and estimation of chemical elements.
Determination of chemical elements in tissues and feces. Tissue and fecal samples were transferred to metal-free digestion vessels (Omni; CEM, United Kingdom) and digested in concentrated HNO 3 with the Microwave Digestion System (MARS; CEM, United Kingdom). Cd, calcium (Ca), zinc (Zn), magnesium (Mg), and iron (Fe) concentrations in the liver and kidneys and Cd levels in the feces were determined by using a flame or graphite furnace atomic absorption spectrophotometer (Spectr AAS or AA; Varian).
Determination of MDA and GSH levels and enzyme activities. The levels of MDA and GSH and the activities of GPx, SOD, CAT, AST, and ALT in the tissues and plasma of mice were measured with an assay kit purchased from the Jiancheng Bioengineering Institute (Nanjing, China). Assays were performed according to the recommendations of the manufacturer. The N-acetyl-␤-D-glucosaminidase (NAG) activity in urine samples was determined colorimetrically with 4-nitrophenyl-N-acetyl-␤-Dglucosamide as the substrate (22) . 
a SM, 0.5 ml skim milk once daily via gavage; PW, plain water for drinking; Cd (in drinking water), CdCl 2 at 100 mg/liter in drinking water; SM ϩ 8610, 1 ϫ 10 9 CFU L. plantarum CCFM8610 in 0.5 ml skim milk once daily via gavage; saline (IP), 0.2 ml saline once daily via intraperitoneal injection; Cd (IP), 9 g CdCl 2 in 0.2 ml saline once daily via intraperitoneal injection. The treatments lasted 8 weeks. 
Determination of MT in tissues.
The metallothionein (MT) content in the liver was determined by a Cd-heme method (23) . Briefly, 0.1 ml of the hepatic homogenate was mixed with 1 ml Tris-HCl buffer (0.03 M, pH 7.8) containing 0.01 mg/liter Cd as CdCl 2 and incubated at room temperature for 5 min to saturate the metal-binding sites of MT. Then 0.1 ml of bovine hemoglobin was added and the samples were heated for 1 min at 100°C and centrifuged at 10,000 ϫ g for 5 min to remove the excess Cd. The MT content was then measured by determining the MT-bound Cd in the supernatant by flame atomic absorption spectrophotometry (Spectr AAS; Varian).
Histopathological studies. Liver and kidney tissues were embedded in paraffin and sectioned at a 5-m thickness with a rotary microtome. The sections were stained with hematoxylin and eosin (H&E) and then examined by light microscopy.
Statistical analysis. Data are expressed as the mean Ϯ the standard error of the mean (SEM) for each group. Differences between groups were evaluated by one-way analysis of variance, followed by the Tukey post hoc test. A P value of Ͻ0.05 was considered to be statistically significant.
RESULTS

Body weight.
All of the mice increased in weight during the experiment, but the Cd-exposed mice in the IP groups appeared to grow more slowly than those in the other groups (Fig. 1) .
Cd levels in the feces, liver, and kidneys. The Cd levels in the feces of mice given Cd orally were much higher than those of all of the other groups (P Ͻ 0.05). The alterations in the fecal Cd levels of the mice in the Cd-only and Cd-plus-CCFM8610 oral groups are presented in Fig. 2 . Compared with the Cd-only group, oral administration of CCFM8610 significantly increased fecal Cd levels at each time point (P Ͻ 0.05), with the exception of the 2nd week. However, compared to the high Cd levels found in the feces of Cd-treated oral groups, the levels of this metal in the feces of Cd-treated IP groups were very low ( Table 2 ). In the IP groups, cotreatment with Cd and CCFM8610 did not alter the fecal Cd levels, compared with those of the Cd-only group.
The Cd levels detected in the livers and kidneys of Cd-treated mice in both the oral and IP groups are shown in Fig. 3 . The tissue Cd concentrations in the control and CCFM8610-only groups were very low (Ͻ0.0001 g/g in the liver and Ͻ0.1 g/g in the kidney), so these data are not included in Fig. 3 . Compared with the control groups, both oral exposure and intraperitoneal injection of Cd increased tissue Cd levels significantly. Cd-plus-CCFM8610 treatment significantly decreased the hepatic and renal Cd levels in the oral groups (P Ͻ 0.05) but failed to decrease tissue Cd accumulation in the mice exposed to Cd via intraperitoneal injection.
As a commercial yogurt starter culture, L. bulgaricus CCFM8004 was used in the animal study for comparison. Com- pared with the Cd-only group, oral administration of CCFM8004 did not significantly increase fecal Cd levels (see Fig. S1 in the supplemental material). Although administration of CCFM8004 caused a slight decrease in Cd accumulation in the livers and kidneys of mice in the oral groups (see Fig. S2 ), there was no statistically significant difference between the Cd-only and Cd-plus-CCFM8004 groups (P Ͼ 0.05). This strain also failed to decrease the tissue Cd levels in the IP groups. Ca, Zn, Fe, and Mg levels in the liver and kidneys. Cd exposure caused alterations of the Ca, Zn, Fe, and Mg metal levels in both the liver and the kidneys (Tables 3 and 4) . Most of these alterations were significantly reversed in the Cd-plus-CCFM8610 groups (P Ͻ 0.05). CCFM8610 treatment by itself did not result in significant differences in the levels of these metal from those in the control groups.
MDA, GSH, SOD, GPx, and CAT in the liver and kidneys. In the liver (Table 5) , MDA levels were increased in both the Cdtreated oral and IP groups (P Ͻ 0.05); this was accompanied by decreases in the GSH levels and SOD, GPx, and CAT activities. Cotreatment with Cd and CCFM8610 significantly protected against the alterations of these parameters in the oral exposure groups. However, in the IP groups, such cotreatment was effective only at restoring the levels of MDA and GSH.
In the kidneys (Table 6 ), chronic Cd exposure caused a marked increase in MDA and decreases in GSH and SOD. Cotreatment with Cd and CCFM8610 had protective effects on MDA, GSH, and SOD in the oral exposure groups (P Ͻ 0.05). In the IP groups, the level of MDA was markedly decreased by CCFM8610 (P Ͻ 0.05), while the other parameters remained unaffected.
As shown in Tables S1 and S2 in the supplemental material, administration of L. bulgaricus CCFM8004 did not protect against the alterations of MDA, GSH, SOD, and CAT levels in the livers and kidneys of mice in both the oral and IP groups. ALT and AST in plasma and NAG in urine. Cd exposure increased ALT, AST, and NAG enzymatic activities (Table 7 ). In the mice treated with Cd plus CCFM8610 in both the oral and IP groups, decreases in all of these markers were observed (P Ͻ 0.05).
MT content in the liver. Hepatic MT protein levels were increased by Cd exposure in both the oral and IP groups (Table 7) . CCFM8610 treatment by itself also caused a significant increase in MT protein levels. In the oral groups, cotreatment with Cd and CCFM8610 reversed the elevation of hepatic MT protein levels caused by Cd exposure (P Ͻ 0.05). However, in the IP groups, cotreatment with Cd and CCFM8610 induced an even higher MT protein level than Cd exposure alone (P Ͻ 0.05).
Histopathological studies. Chronic Cd exposure, especially by intraperitoneal injection, caused significant damage to the tissues of mice. Representative photomicrographs of hepatic and renal tissue samples from the IP groups are shown in Fig. 4 and 5. Cd exposure caused histological changes in the liver, including loss of intact liver plates, chromatin condensation, and cytoplasmic vacuolization. Cotreatment with Cd and CCFM8610 significantly alleviated such hepatic injury. In the kidneys, cloudy swelling and necrosis of tubules and dilation of glomeruli were evident in Cdonly-treated animals, in contrast to the control group. With the exception of some swollen glomeruli, cotreatment with Cd and CCFM8610 showed protective effects against such renal damage. It was also observed that the hepatic and renal morphology of the CCFM8610-only group did not differ from that of the control groups. 
DISCUSSION
In our previous study, L. plantarum CCFM8610, a selected lactobacillus with good Cd-binding ability in vitro, was shown to have protective effects against acute Cd toxicity in mice (17) . The intestinal Cd sequestration ability of CCFM8610 appeared to be important, but it was unclear whether all of its protective effects can be attributed to this single protection route. On the other hand, it is important to evaluate the protective effects of CCFM8610 against chronic Cd toxicity, since chronic exposure is more commonly reported and is a greater threat to human and animal health than acute intoxication (3, 4) . This study provides biological evidence that L. plantarum CCFM8610 can alleviate chronic Cd toxicity in mice and that the protective function is not limited to intestinal Cd sequestration.
To mimic chronic exposure, we delivered Cd orally via drinking water, the concentration of which was selected according to the average human Cd intake and animal body Cd levels in polluted areas, for modeling of environmentally relevant, low-concentration Cd exposure (18) (19) (20) (21) . Our results show that when Cd is introduced orally, treatment with L. plantarum CCFM8610 decreases intestinal Cd absorption by increasing fecal Cd excretion (Fig. 2) , an effect that can be attributed to its good Cd sequestration capability (17) . In addition, CCFM8610 also decreases tissue Cd accumulation (Fig. 3) , reduces lipid peroxidation, and protects the activities of GPx, SOD, and CAT, which are known to be associated with antioxidant defense systems (Tables 5 and 6 ). These results are consistent with our previous acute Cd toxicity study (17) . AST and ALT are specific markers of Cd-induced hepatic damage (24, 25) , and NAG is considered to be the best urine marker of Cd-induced renal damage (26, 27) . The restoration of these biological parameters in the mice that were given CCFM8610 orally further confirms the protective effects of this strain against chronic Cd toxicity.
The reduced Cd uptake caused by intestinal Cd sequestration by CCFM8610 can instigate downstream protective effects on alleviation of Cd toxicity. However, the possibility that CCFM8610 can induce alternative regulatory mechanisms that provide protection against Cd toxicity cannot be ruled out. To evaluate the latter, we bypassed the sequestration route by introducing Cd directly into mice via intraperitoneal injection, thus avoiding direct contact of the metal with CCFM8610. Intraperitoneal injection led to higher tissue Cd levels than oral exposure, which may be due to the discrepancies between the intestinal Cd absorption rate described in the literature and the absorption rate of the mice used in this experiment. As a consequence and in contrast to oral Cd administration, we did not observe any significant difference in the fecal Cd levels between the Cd-only and Cd-plus-CCFM8610 groups (Table 2) . It has been previously reported that after accumulating in the liver, a small amount of Cd is re-excreted into the intestinal tract via bile and then rapidly reabsorbed by intestinal epithelial cells (28, 29) . It is thus possible that intestinal CCFM8610 may bind such re-excreted Cd before intestinal absorption and then be excreted with the feces. This could explain the increase in the fecal Cd levels of the Cd-plus-CCFM8610 IP group in the 2nd and 4th weeks, even though there is no direct contact between Cd and CCFM8610. However, the levels of re- a Values are for 10 mice per group. The letters a to c in parentheses indicate statistically significant differences (P Ͻ 0.05) between the oral groups in each row. The letters A to C in parentheses indicate statistically significant differences (P Ͻ 0.05) between the IP groups in each row. Oral, oral groups; IP, IP groups; 8610, L. plantarum CCFM8610.
excreted Cd seem to be too low to affect the total Cd intake, which is confirmed by the lack of significant differences between tissue Cd levels in the Cd-only and Cd-plus-CCFM8610 IP groups (Fig.  3) . On the basis of this analysis, it can be concluded that when mice are exposed to Cd via intraperitoneal injection, CCFM8610 is unable to significantly sequester Cd in the intestines, thus losing its effect on Cd absorption and tissue accumulation.
In the mice that were intraperitoneally injected, the Cd-induced reduction of activities of SOD, GPx, and CAT was not altered by CCFM8610 administration (Tables 5 and 6 ), in contrast to the significant protection of these enzymes by CCFM8610 administration in the oral groups, as discussed above. We believe this is a reflection of the differences in the tissue Cd levels of mice that receive Cd via these two different routes. However, compared with the Cd-only group, cotreatment with Cd and CCFM8610 in the IP groups significantly decreased the MDA levels in the liver and kidneys and alleviated the Cd-induced increases in AST, ALT, and NAG (Table 7) . Moreover, CCFM8610 administration prevented tissue damage in the IP groups (Fig. 4 and 5) . It is well known that oxidative stress is an important mechanism of both acute and chronic Cd toxicity, which leads to changes in hepatic and renal biomarkers and tissue histopathology (18, 30) . MDA acts as an indicator of the lipid peroxidation process. The decreases in tissue MDA levels in the Cd-plus-CCM8610 IP group indicates that CCFM8610 is able to alleviate oxidative stress even when it is unable to sequester Cd and reduce its accumulation in tissue. It is therefore possible that CCFM8610 can directly mitigate Cd-induced oxidative stress through other pathways, which somehow counteracts the Cd-induced alterations of AST, ALT, and NAG and tissue histopathological changes. In the animal study comparing CCFM8610 and CCFM8004, the results, including fecal Cd excretion, tissue Cd accumulation, and MDA levels in the livers and kidneys of mice, showed that CCFM8004 was unable to exhibit the same protective effects against chronic Cd toxicity as CCFM8610. The failure of protection in the oral groups can be explained by the less effective intestinal Cd sequestration of CCFM8004, which was discussed in our previous report (17) . However, in the IP groups, the intestinal Cd sequestration ability of both strains was bypassed. Therefore, the differences between the protective effects of CCFM8610 and CCFM8004 in the IP groups indicated that CCFM8610 had a special antioxidant action mode that did not exist in a commercial yogurt starter culture, L. bulgaricus CCFM8004. What needs to be mentioned is that this direct protection of CCFM8610 against oxidative stress is unlikely to be mediated via protection against a Cd-induced decrease in antioxidant enzyme activities, since no significant difference between the antioxidant enzyme activities of the Cd-only and Cdplus-CCM8610 IP groups can be found.
MT is a low-molecular-weight protein that has a high affinity for Cd and other divalent cations (31) . Tissue MT levels have beern reported to be significantly elevated with Cd accumulation in humans and animals (32) (33) (34) (35) . Consistent with these reports, treatment with Cd (via both drinking water and intraperitoneal injection) sharply increases the MT protein level in the liver. In oral groups, cotreatment with Cd and CCFM8610 causes a decrease in MT protein in the liver compared with that in the Cdonly group, which may be a result of CCFM8610-induced reduction of Cd uptake. More importantly, MT is reported to be critical for protecting humans and animals from Cd toxicity (36) . It not only plays a role in binding and detoxifying Cd in tissue but is also an effective free-radical scavenger that protects against Cd-induced oxidative stress (37) (38) (39) . In this study, it was found that treatment with CCFM8610 alone causes a significant increase in the MT protein level in the liver. This indicates that CCFM8610 may be capable of helping its host to improve MT production. This is further supported by the fact that the MT protein level in the Cd-plus-CCFM8610 IP group was significantly higher than that in the Cd-only IP group. As no obvious difference between the tissue Cd levels of these two groups was found, the higher MT level in the Cd-plus-CCFM8610 IP group should be a reflection of MT induction by CCFM8610, which provides further evidence of the direct anti-oxidative-stress property of CCFM8610. Supporting our findings, rodent treatment with a flavonoid (24) or Ganoderma lucidum spores (40) has been used to increase the MT level in tissues, which in turn offers protection against Cd-induced oxidative stress.
In addition to MT induction, there may be other mechanisms involved in the direct anti-oxidative-stress protection of CCFM8610. According to the global transcriptomic analysis of mouse tissue from the Cd-only and Cd-plus-CCFM8610 IP groups (Q. Zhai, F. W. Tian, and W. Chen, unpublished data), cotreatment with Cd and CCFM8610 caused gene expression changes in several Cd-toxicity-related pathways. For example, several genes in the mitogen-activated protein kinases (MAPK) pathways were upregulated in response to chronic Cd toxicity in the liver. The activation of MAPKs by Cd is associated with the enhanced production of reactive oxygen species (ROS) and can play an important role in Cd-induced cellular apoptosis (41) (42) (43) . Interestingly, cotreatment with Cd and CCFM8610 reverses some of these gene expression alterations in the MAPK pathway, indicating that the anti-oxidative-stress effect of CCFM8610 may be related to the regulation of these signal transduction pathways, which in turn decreases ROS production and prevents Cd-induced cellular apoptosis. On the basis of these analyses, we propose that L. plantarum CCFM8610 can protect against chronic Cd toxicity via two parallel routes (Fig. 6 ). As well as being able to sequester Cd in the gut, thus reducing tissue Cd accumulation, CCFM8610 can also offer direct protection against oxidative stress, leading to the prevention of Cd-induced tissue damage.
Besides the protective effects of CCFM8610 against Cd toxicity, its safety was also evaluated. CCFM8610 by itself does not cause a loss of essential metals, including Ca, Zn, Fe, and Mg, from the tissues of mice (Tables 3 and 4) . Some essential elements even increase in concentration, such as Ca in the liver and Fe in the kidneys. This may be attributed to the ability of CCFM8610 to increase tissue MT levels, as MT is also effective in binding other divalent cations in addition to Cd (31) . Taking other effects, such as body weight gain, oxidative stress status, hepatic and renal damage biomarkers, and histopathological changes, into consideration, we believe that CCFM8610 treatment is safe.
In conclusion, this study has demonstrated that L. plantarum CCFM8610 has protective effects against chronic Cd toxicity in mice. This strain was able to decrease intestinal Cd absorption, reduce tissue Cd accumulation, alleviate tissue oxidative stress, reverse changes in hepatic and renal damage biomarkers, and ameliorate tissue histopathological changes without loss of essential metals. We also confirmed that along with the initial intestinal Cd sequestration, CCFM8610 treatment can offer other direct protection against Cd-induced oxidative stress.
